Literature DB >> 26384790

Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer.

Gregory M Gressel1, Vinita Parkash2, Lubna Pal3.   

Abstract

BACKGROUND: Definitive management with hysterectomy could be appropriate for some patients with endometrial cancer and its precursor lesions, but poses challenges for those desiring future fertility.
OBJECTIVES: To review risk factors for endometrial hyperplasia/cancer among premenopausal women and discuss management options for fertility preservation. SEARCH STRATEGY: A literature search through the PubMed, Ovid, and Cochrane databases was conducted using the terms "endometrial hyperplasia" and "endometrial cancer," cross-referenced with "fertility preservation." SELECTION CRITERIA: All articles published in English between January 1, 2000, and January 1, 2015, were considered if they were readily available online. DATA COLLECTION AND ANALYSIS: Articles were analyzed and information was synthesized into a comprehensive review. MAIN
RESULTS: Chronic anovulation, obesity, polycystic ovarian syndrome, metabolic syndrome, insulin resistance, and type 2 diabetes mellitus must be appreciated as risk factors for endometrial pathology. Providers must exert vigilance in identifying patients at risk and in initiating pre-emptive strategies. Risk reduction with lifestyle modification, weight loss, and glycemic control can improve regression and overall health. Fertility outcomes for these patients are promising, especially with assisted reproductive technology.
CONCLUSIONS: Conservative management could be appropriate for carefully selected women with complex atypical endometrial hyperplasia or early-stage endometrial cancer who desire future fertility.
Copyright © 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Complex atypical endometrial hyperplasia; Early-stage endometrial cancer; Fertility preservation; Progestin therapy

Mesh:

Year:  2015        PMID: 26384790     DOI: 10.1016/j.ijgo.2015.06.031

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  15 in total

1.  Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo.

Authors:  Aliyah Almomen; Elke A Jarboe; Mark K Dodson; C Matthew Peterson; Shawn C Owen; Margit M Janát-Amsbury
Journal:  Pharm Res       Date:  2016-05-31       Impact factor: 4.200

Review 2.  [Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].

Authors:  F Kommoss; S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

3.  Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment.

Authors:  Shuang Zhou; Zhiying Xu; Bingyi Yang; Jun Guan; Weiwei Shan; Yue Shi; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2021-07       Impact factor: 4.401

Review 4.  Fertility-preservation in endometrial cancer: is it safe? Review of the literature.

Authors:  Márcia Mendonça Carneiro; Rívia Mara Lamaita; Márcia Cristina França Ferreira; Agnaldo Lopes Silva-Filho
Journal:  JBRA Assist Reprod       Date:  2016-12-01

5.  Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age.

Authors:  Yoshinori Okamura; Fumitaka Saito; Kiyomi Takaishi; Takeshi Motohara; Ritsuo Honda; Takashi Ohba; Hidetaka Katabuchi
Journal:  Reprod Med Biol       Date:  2016-12-05

6.  Activating transcription factor 3 inhibits endometrial carcinoma aggressiveness via JunB suppression.

Authors:  Fangyuan Wang; Jingjing Li; Haixia Wang; Fan Zhang; Jin Gao
Journal:  Int J Oncol       Date:  2020-06-19       Impact factor: 5.650

7.  Bariatric surgery after failed conservative management in a morbidly obese patient with endometrial cancer.

Authors:  Lauren Montemorano; Stacy A Smrz; Anahita D Jalilvand; Sabrena F Noria; Ritu Salani
Journal:  Gynecol Oncol Rep       Date:  2019-01-16

8.  Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis.

Authors:  Miaomiao Li; Tao Guo; Ran Cui; Ying Feng; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Manag Res       Date:  2019-05-06       Impact factor: 3.602

9.  Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.

Authors:  Joseph A Dottino; Qian Zhang; David S Loose; Bryan Fellman; Brenda D Melendez; Mikayla S Borthwick; Laurie J McKenzie; Ying Yuan; Richard K Yang; Russell R Broaddus; Karen H Lu; Pamela T Soliman; Melinda S Yates
Journal:  Am J Obstet Gynecol       Date:  2020-08-21       Impact factor: 8.661

10.  PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer.

Authors:  Li-Ling Lin; Edward R Kost; Chun-Lin Lin; Philip Valente; Chiou-Miin Wang; Mikhail G Kolonin; Alexes C Daquinag; Xi Tan; Nicholas Lucio; Chia-Nung Hung; Chen-Pin Wang; Nameer B Kirma; Tim H-M Huang
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.